CStone Approved for US Trial of ROR1 ADC
publication date: Jan 3, 2022
Suzhou CStone Pharma was approved to start a US Phase I trial of an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is an oncofetal protein with low or no expression in adult tissues but high expression in various leukemias and non-Hodgkin lymphoma, breast, lung and ovarian cancers. The candidate, CS5001, will be one of the three ROR1 ADCs globally to start clinical trials. In 2020, CStone acquired global rights (ex-Korea) to CS5001 from LegoChem Bio in a $363 million deal, plus royalties. More details....
Stock Symbols: (HK: 2616) (KOSDAQ: 141080)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.